SIBN: si-bone.com Growth-Adjusted Market Cap to Net Income
SI-BONE, Inc. (SIBN) possesses significant pricing power over its niche implants due to surgeon loyalty. The normalized PEG ratio visualizes this market position, where 0.00 represents the latest level. Meanwhile, the company minimizes production waste in accordance with ESG standards and seeks to mitigate the risks of global metal supply chain disruptions.
SI-BONE, Inc. (SIBN) - metric breakdowns and financial figures
- current price and projected stock value:
- market capitalization information:
- company book value details:
- business debt structure and liquidity details:
- earnings and valuation multiples indicators:
SIBN - Net Profit|Company Profit Forecast SI-BONE, Inc.|SIBN - P/E Multiple|Projected Price to Earnings SI-BONE Medical|SIBN - PEG Multiple|EV/EBITDA Multiple SI-BONE Corp|SIBN - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months SI-BONE|SIBN - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months si-bone.com|SIBN - Earnings growth in current year|Expected net earnings per share growth next year SI-BONE, Inc.
Fundamental company analysis:SIBN (SI-BONE Inc)
The rapid adoption of innovative SI-BONE implants into surgical practice provides the company with strong profit dynamics, making the PEG ratio analysis critically important. This PEG chart correlates the asset's market value with its expansion rate: a value below one signals that the business is undervalued relative to its growth potential, allowing investors to identify undervalued assets with high returns.
Competing companies
Price/Earnings to Growth Ratio BSX (Boston Scientific Corp)|PEG Multiple EW (Edwards Lifesciences Corp)|Growth-Adjusted Market Cap to Net Income ResMed Corporation (RMD)|PODD: Price/Earnings to Growth Multiple|Market Cap to Earnings and Growth Ratio ZBH|COO: PEG Multiple|Price to Earnings Adjusted for Growth Rate Invisalign (ALGN)|GMED (Globus Medical Corp) - PEG Multiple|Growth-Adjusted P/E Ratio TMDX (transmedics.com)|Price/Earnings to Growth Multiple ATEC (Alphatec Holdings, Inc.)|AORT (artivion.com) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Enovis ENOV|IART - Price/Earnings to Growth Multiple|Motiva - PEG Multiple|Price to Earnings Adjusted for Growth Rate iLet Bionic Pancreas|IRMD: PEG Multiple|Growth-Adjusted P/E Ratio EMBC|TNDM (Tandem Diabetes Care, Inc.) - PEG Multiple|AxoGen Inc (AXGN) - Growth-Adjusted Market Cap to Net Income|PEG Multiple OFIX|Price/Earnings to Growth Multiple Bioventus Global BVS|PEG Multiple KIDS (OrthoPediatrics)|PEG Multiple treace.com TMCI|SRTA - Price/Earnings to Growth Ratio|CARL: Price/Earnings to Growth Ratio|RXST (RxSight Corp) - Price/Earnings to Growth Multiple|ClearPoint Neuro - Growth-Adjusted Payback Ratio|STXS (Stereotaxis, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate neurostar.com STIM|Price/Earnings to Growth Ratio Sight Sciences (SGHT)|Orchestra BioMed Inc. (OBIO) - Price to Net Income Growth Ratio|Anika Therapeutics, Inc. - Price/Earnings to Growth Multiple|PEG Multiple InspireMD Inc. NSPR|Jin Medical International Ltd - PEG Multiple|Growth-Adjusted Market Cap to Net Income Vivani Medical, Inc. VANI|xtantmedical.com (XTNT) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMTC (NeuroOne)|Price/Earnings to Growth Ratio Modular Medical Inc|Price/Earnings to Growth Multiple Myomo Inc (MYO)|PEG Multiple COCH|VVOS - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio enVVeno Medical Corp. NVNO|SINT: Growth-Adjusted P/E Ratio|TNON: Price/Earnings to Growth Multiple|Lifeward Ltd. - Company Value to Earnings Growth Ratio|autonomix.com (AMIX) - Price/Earnings to Growth Ratio|IVF - Growth-Adjusted Market Cap to Net Income|BBLG (Bone Biologics Corp) - PEG Multiple|Axonics Inc. (AXNX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple BIOL (Biolase, Inc.)|dynatronics.com (DYNT) - Price to Net Income Growth Ratio|PEG Multiple FNA (Paragon 28)|INVO Bioscience Inc. - Price/Earnings to Growth Ratio
